Traws PharmaTRAW
13F holders, Q4 2024 (December 31)At the end of Q4 2024, 18 institutions reported holding Traws Pharma Inc. (TRAW) in their 13F filings, up 7 from Q3 2024. 8 opened new positions and 2 sold out. The largest holders were Orbimed Advisors LLC ($5.4M), Perceptive Advisors LLC ($1.5M) and Alyeska Investment Group, L.P. ($1.0M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Traws Pharma Inc.
- CUSIP
- 68232V884
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $4.5M |
| Exits | 2 | $2K |
All 13F filers, Q3 2024 → Q4 2024: 539,917 shares bought and 16,029 shares sold, net +523,888 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Orbimed Advisors LLC | 0.11% | No change | 605,531 | $5.4M |
| Perceptive Advisors LLC | 0.04% | New | 164,157 | $1.5M |
| Alyeska Investment Group, L.P. | 0.00% | New | 116,714 | $1.0M |
| Ikarian Capital, LLC | 0.25% | New | 98,493 | $875K |
| Vestal Point Capital, LP | 0.04% | New | 75,000 | $666K |
| Geode Capital Management, LLC | 0.00% | New | 20,801 | $185K |
| Morgan Stanley | 0.00% | Add +2057.1% | 15,725 | $140K |
| Vanguard Group Inc. | 0.00% | Reduce -50.8% | 13,141 | $117K |
| Boothbay Fund Management, LLC | 0.00% | New | 28,431 | $108K |
| Renaissance Technologies | 0.00% | New | 10,052 | $89K |
| Millennium Management | 0.00% | New | 10,012 | $89K |
| BlackRock, Inc. | 0.00% | No change | 9,956 | $88K |
| Group One Trading LLC | 0.00% | Add +1718.8% | 1,164 | $10K |
| UBS Group AG | 0.00% | Add +25.6% | 791 | $7K |
| Vermillion & White Wealth Management Group, LLC | 0.00% | No change | 205 | $2K |
| SBI Securities Co., Ltd. | 0.00% | — | 155 | $1K |
| Bank of America Corp. | 0.00% | Reduce -96.5% | 76 | $675 |
| Pacific Capital Wealth Advisors, Inc. | 0.00% | No change | 2 | $18 |
"% of holder's portfolio" is TRAW's weight in each manager's 13F, not the share of Traws Pharma Inc. the manager owns.